Paul J. Mellett - Nov 19, 2021 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role: Treasurer and CFO
Signature: /s/ Nathaniel S. Gardiner as attorney-in-fact
Stock symbol: ENTA
Transactions as of: Nov 19, 2021
Transactions value $: $0
Form type: 4
Date filed: 11/23/2021, 06:31 PM
Next filing: Dec 3, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENTA	Common Stock	Award	$0	+6.8K	+13.67%	$0.00	56.6K	Nov 19, 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENTA	Stock Option (right to buy)	Award	$0	+28.4K		$0.00	28.4K	Nov 19, 2021	Common Stock	28.4K	$75.33	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 19, 2021). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements.
F2	The amount of securities beneficially owned by the reporting person was incorrectly stated on the Form 4 filed on January 8, 2021 as "61,759" instead of "49,759." The amount of securities beneficially owned, as reported in column 5 of this Form 4, corrects this error.
F3	Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021).